Cargando…

Safety and Plasma Concentrations of a Cyclin-dependent Kinase 9 (CDK9) Inhibitor, FIT039, Administered by a Single Adhesive Skin Patch Applied on Normal Skin and Cutaneous Warts

BACKGROUND: Cutaneous warts are caused by human papilloma virus (HPV) infection. FIT039, a specific inhibitor of CDK9, suppresses the proliferation of DNA viruses in vitro. PURPOSE: We evaluated the safety, plasma concentrations, and efficacy of FIT039 delivered by single application of an adhesive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sumi, Eriko, Nomura, Takashi, Asada, Ryuta, Uozumi, Ryuji, Tada, Harue, Amino, Yoko, Sawada, Teruo, Yonezawa, Atsushi, Hagiwara, Masatoshi, Kabashima, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510824/ https://www.ncbi.nlm.nih.gov/pubmed/30284700 http://dx.doi.org/10.1007/s40261-018-0712-7

Ejemplares similares

The efficacy of a cyclin dependent kinase 9 (CDK9) inhibitor, FIT039, on verruca vulgaris: study protocol for a randomized controlled trial
por: Nomura, Takashi, et al.
Publicado: (2019)

Safety and Efficacy of FIT039 for Verruca Vulgaris: A Placebo-Controlled, Phase I/II Randomized Controlled Trial
por: Nomura, Takashi, et al.
Publicado: (2021)

Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy
por: Sakamoto, Tetsunori, et al.
Publicado: (2023)

Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target
por: Kryštof, Vladimír, et al.
Publicado: (2012)

Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma
por: Ma, Hangzhan, et al.
Publicado: (2018)

Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer
por: Parvathareddy, Sandeep Kumar, et al.
Publicado: (2021)

T.03.9 MUTYH-ASSOCIATED POLYPOSIS: IS TIME TO CHANGE UPPER GI SURVEILLANCE?
por: Sanchez-Mete, L., et al.
Publicado: (2022)

The Use of Common Warts of the Hand in Skin Grafting
Publicado: (1878)

MD simulation of the Tat/Cyclin T1/CDK9 complex revealing the hidden catalytic cavity within the CDK9 molecule upon Tat binding
por: Asamitsu, Kaori, et al.
Publicado: (2017)

Pyrazole-Curcumin Suppresses Cardiomyocyte Hypertrophy by Disrupting the CDK9/CyclinT1 Complex
por: Funamoto, Masafumi, et al.
Publicado: (2022)

Identification and Functional Characterisation of CRK12:CYC9, a Novel Cyclin-Dependent Kinase (CDK)-Cyclin Complex in Trypanosoma brucei
por: Monnerat, Séverine, et al.
Publicado: (2013)

Transcriptome analysis of HPV-induced warts and healthy skin in humans
por: AL-Eitan, Laith N., et al.
Publicado: (2020)

Cyclin K goes with Cdk12 and Cdk13
por: Kohoutek, Jiri, et al.
Publicado: (2012)

Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9
por: Saqub, Hera, et al.
Publicado: (2020)

Molecular docking analysis of piperine with CDK2,CDK4,Cyclin D and Cyclin T proteins
por: Rekha, Umapathy Vidhya, et al.
Publicado: (2020)

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Atuveciclib Suppresses Intervertebral Disk Degeneration via the Inhibition of the NF-κB Signaling Pathway
por: Ni, Weiyu, et al.
Publicado: (2020)

Gene Expression Profiling of MicroRNAs in HPV-Induced Warts and Normal Skin
por: AL-Eitan, Laith N., et al.
Publicado: (2019)

An Improved Protocol for Comprehensive Etiological Characterization of Skin Warts and Determining Causative Human Papillomavirus Types in 128 Histologically Confirmed Common Warts
por: Skubic, Lucijan, et al.
Publicado: (2022)

Nuclear Import of Cdk/Cyclin Complexes: Identification of Distinct Mechanisms for Import of Cdk2/Cyclin E and Cdc2/Cyclin B1
por: Moore, Jonathan D., et al.
Publicado: (1999)

Targeting CDK9 for the Treatment of Glioblastoma
por: Ranjan, Alice, et al.
Publicado: (2021)

Phosphorylation of Rad9 at Serine 328 by Cyclin A-Cdk2 Triggers Apoptosis via Interfering Bcl-xL
por: Zhan, Zhuo, et al.
Publicado: (2012)

Inhibition of the CDK9–cyclin T1 protein–protein interaction as a new approach against triple-negative breast cancer
por: Cheng, Sha-Sha, et al.
Publicado: (2022)

HPV Vaccination in Immunosuppressed Patients with Established Skin Warts and Non-Melanoma Skin Cancer: A Single-Institutional Cohort Study
por: Bossart, Simon, et al.
Publicado: (2023)

Novel insights into the role of immune cells in skin and inducible skin-associated lymphoid tissue (iSALT)
por: Ono, Sachiko, et al.
Publicado: (2015)

Cell cycle progression mechanisms: slower cyclin-D/CDK4 activation and faster cyclin-E/CDK2
por: Zhang, Wengang, et al.
Publicado: (2023)

Identification of a novel CDK9 inhibitor targeting the intramolecular hidden cavity of CDK9 induced by Tat binding
por: Asamitsu, Kaori, et al.
Publicado: (2022)

The CDK9/Cyclin T1 subunits of P-TEFb in mouse oocytes and preimplantation embryos: A possible role in embryonic genome activation
por: Oqani, Reza K, et al.
Publicado: (2011)

Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia
por: Yeh, Yuh-Ying, et al.
Publicado: (2014)

The CDK9–cyclin T1 complex mediates saturated fatty acid–induced vascular calcification by inducing expression of the transcription factor CHOP
por: Shiozaki, Yuji, et al.
Publicado: (2018)

Safety of Silk-elastin Sponges in Patients with Chronic Skin Ulcers: A Phase I/II, Single-center, Open-label, Single-arm Clinical Trial
por: Noda, Kazuo, et al.
Publicado: (2021)

Human papillomavirus–related condyloma on keratinized skin
por: Egawa, Gyohei, et al.
Publicado: (2022)

Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma
por: Matsumoto, M, et al.
Publicado: (1999)

Regulation of CDK9 Activity by Phosphorylation and Dephosphorylation
por: Nekhai, Sergei, et al.
Publicado: (2014)

CDK9 inhibitors in acute myeloid leukemia
por: Boffo, Silvia, et al.
Publicado: (2018)

Targeting CDK9 for treatment of colorectal cancer
por: Rahaman, Muhammed H., et al.
Publicado: (2019)

Targeting CDK9 for Anti-Cancer Therapeutics
por: Mandal, Ranadip, et al.
Publicado: (2021)

The Prognostic Role of CDK9 in Bladder Cancer
por: Borowczak, Jędrzej, et al.
Publicado: (2022)

Regulation of blood vascular permeability in the skin
por: Ono, Sachiko, et al.
Publicado: (2017)

Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067
por: Shen, Shen, et al.
Publicado: (2020)

Title unknown, CERN-ALEPH-PHYSIC-96-039
por: CERN. Geneva. ALEPH
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_0rev8ucgnia4mocpgl4i3l5gpi